Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“How would a world without BCG look like?
- Pros for BCG outlined by Gianluca Giannarini: efficacy, costs plus shortage not a problem
- Counter part addressed by Laura S. Mertens: maintenance is most critical to generate efficacy plus toxicity not negligible.”
Read more posts featuring BCG on OncoDaily.com.
